88 related articles for article (PubMed ID: 19087569)
21. Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer.
Glud E; Kjaer SK; Thomsen BL; Høgdall C; Christensen L; Høgdall E; Bock JE; Blaakaer J
Arch Intern Med; 2004 Nov; 164(20):2253-9. PubMed ID: 15534163
[TBL] [Abstract][Full Text] [Related]
22. [Correlation of preoperative serum vascular endothelial growth factor level with CA125 level in patients with epithelial ovarian cancer and its prognostic value].
Tan XJ; Lang JH; Shen K; Wang L; Wu M; Xu XY
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):9-12. PubMed ID: 18366924
[TBL] [Abstract][Full Text] [Related]
23. Factors associated with estrogen receptors-alpha (ER-alpha) and -beta (ER-beta) and progesterone receptor abundance in obese and non obese pre- and post-menopausal women.
Meza-Muñoz DE; Fajardo ME; Pérez-Luque EL; Malacara JM
Steroids; 2006 Jun; 71(6):498-503. PubMed ID: 16566954
[TBL] [Abstract][Full Text] [Related]
24. VEGF-A and i-NOS expression are prognostic factors in serous epithelial ovarian carcinomas after complete surgical resection.
Engels K; du Bois A; Harter P; Fisseler-Eckhoff A; Kommoss F; Stauber R; Kaufmann M; Nekljudova V; Loibl S
J Clin Pathol; 2009 May; 62(5):448-54. PubMed ID: 19126566
[TBL] [Abstract][Full Text] [Related]
25. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer.
Lee P; Rosen DG; Zhu C; Silva EG; Liu J
Gynecol Oncol; 2005 Mar; 96(3):671-7. PubMed ID: 15721410
[TBL] [Abstract][Full Text] [Related]
26. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
[TBL] [Abstract][Full Text] [Related]
27. Menopausal hormone therapy and breast cancer phenotype: does dose matter?
Garwood ER; Kumar AS; Shim V
Ann Surg Oncol; 2008 Sep; 15(9):2526-32. PubMed ID: 18618187
[TBL] [Abstract][Full Text] [Related]
28. Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications.
Garzetti GG; Ciavattini A; Lucarini G; Goteri G; de e Nictolis M; Garbisa S; Masiero L; Romanini C; Graziella B
Anticancer Res; 1995; 15(6B):2799-804. PubMed ID: 8669868
[TBL] [Abstract][Full Text] [Related]
29. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
[TBL] [Abstract][Full Text] [Related]
30. Acupuncture versus venlafaxine for the management of vasomotor symptoms in patients with hormone receptor-positive breast cancer: a randomized controlled trial.
Walker EM; Rodriguez AI; Kohn B; Ball RM; Pegg J; Pocock JR; Nunez R; Peterson E; Jakary S; Levine RA
J Clin Oncol; 2010 Feb; 28(4):634-40. PubMed ID: 20038728
[TBL] [Abstract][Full Text] [Related]
31. Analysis of the expression of estrogen receptor, progesterone receptor and chicken ovalbumin upstream promoter-transcription factor I in ovarian epithelial cancers and normal ovaries.
De Sousa Damião R; Fujiyama Oshima CT; Stávale JN; Gonçalves WJ
Oncol Rep; 2007 Jul; 18(1):25-32. PubMed ID: 17549341
[TBL] [Abstract][Full Text] [Related]
32. [Expression of heat shock protein-70, estrogen receptor and progesterone receptor in ovarian carcinomas and the correlation between HSP70 and sex steroid receptor].
Xing Y; Tang Z; Liao Y; Zhu SF; Li ZM; Chen ML
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Jul; 35(4):486-8. PubMed ID: 15291106
[TBL] [Abstract][Full Text] [Related]
33. [Morphometrical and immunohistochemical criteria of prognosis in patients with serous and mucinous ovarian carcinoma].
Kolosov AE; Novichkov EV
Arkh Patol; 2003; 65(5):29-32. PubMed ID: 14664145
[TBL] [Abstract][Full Text] [Related]
34. Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer.
Takao M; Okamoto A; Nikaido T; Urashima M; Takakura S; Saito M; Saito M; Okamoto S; Takikawa O; Sasaki H; Yasuda M; Ochiai K; Tanaka T
Oncol Rep; 2007 Jun; 17(6):1333-9. PubMed ID: 17487387
[TBL] [Abstract][Full Text] [Related]
35. [Recurrence risk factors of platinum-sensitive epithelial ovarian cancer].
Yan XJ; Liang LZ; Zeng ZY; Liu JH; Yuan SH; Wei M
Ai Zheng; 2005 Jun; 24(6):751-4. PubMed ID: 15946495
[TBL] [Abstract][Full Text] [Related]
36. [Impact of dose delivery of postoperative first-line chemotherapy on prognosis of stage III C epithelial ovarian carcinoma].
Zhao XD; Zhang Q; Zhang Y
Ai Zheng; 2005 Aug; 24(8):1002-5. PubMed ID: 16086882
[TBL] [Abstract][Full Text] [Related]
37. Impact of second look laparotomy and secondary cytoreductive surgery at second-look laparotomy in ovarian cancer patients.
Obermair A; Sevelda P
Acta Obstet Gynecol Scand; 2001 May; 80(5):432-6. PubMed ID: 11328220
[TBL] [Abstract][Full Text] [Related]
38. Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: correlation with DNA flow cytometry, biochemical receptor assay, and patient survival.
Isola J; Kallioniemi OP; Korte JM; Wahlström T; Aine R; Helle M; Helin H
J Pathol; 1990 Dec; 162(4):295-301. PubMed ID: 2290114
[TBL] [Abstract][Full Text] [Related]
39. Ratio of concentrations of estrogen receptors to progesterone receptors (ER/PR) in the cytosol of breast cancers (stratification by forming of groups differing in PR).
Hochmann J
Neoplasma; 2007; 54(4):290-6. PubMed ID: 17822318
[TBL] [Abstract][Full Text] [Related]
40. Epithelial ovarian tumors in the reproductive age group: age is not an independent prognostic factor.
Massi D; Susini T; Savino L; Boddi V; Amunni G; Colafranceschi M
Cancer; 1996 Mar; 77(6):1131-6. PubMed ID: 8635134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
